In addition, Zepbound has not been studied in patients with a history of pancreas inflammation (pancreatitis) or severe gastrointestinal disease (including severe gastroparesis, a condition that affects normal movement of the muscles in the stomach), according to the FDA
Once you know the big pharmaceutical companies are spending a lot of money looking for glucagon receptor antagonists and testing them, and GIP receptor antagonists and testing them, it requires a lot of gusto, a lot of lunacy and craziness to say, nah, I believe all these big pharmaceutical companies are wrong, my lab is doing the opposite. But now, the sentiment has drastically shifted and many companies are looking to co-agonist drugs to achieve over 20%, or even close to 30% weight loss
The Wegovy injection is FDA-approved for weight loss in adults and children aged 12 and older with obesity and adults with overweight and at least one weight-related medical condition
Rapid weight loss during GLP-1 therapy mobilizes stored vitamin D from fat tissue, accelerating depletion